Hikma Pharmaceuticals USA Inc.
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
8
Ending by 2030
Dec 2026
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 23, 2027The maintenance fee for Luer connection adapters for retractable needle syringes (US 10,357,621) comes due Jan 23, 2027. Unpaid by Jul 23, 2027, it lapses early.
- 2 fees due Feb 6 to 28, 2027 · next Feb 6
- 3 fees due Mar 5 to 26, 2027 · next Mar 5
- 2 fees due Apr 3 to 15, 2027 · next Apr 3
- 3 fees due Jun 10 to 15, 2027 · next Jun 10
- 1 fee due Sep 12, 2027The maintenance fee for Liquid composition comprising glucose (US 11,925,703) comes due Sep 12, 2027. Unpaid by Mar 13, 2028, it lapses early.
- 3 fees due Oct 14 to 16, 2027 · next Oct 14
- 1 fee due Nov 7, 2027The maintenance fee for Liquid naloxone spray (US 11,975,096) comes due Nov 7, 2027. Unpaid by May 8, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,060,951 | Formulation and manufacturing process for calcium acetate capsules In force · USPTO record | In force | USPTO record | |
| US 10,300,020 | Formulation and manufacturing process for calcium acetate capsules In force · USPTO record | In force | USPTO record | |
| US D687,894 | Intravenous Bag/Line Safety Label In force · High confidence | In force | High confidence | |
| US 8,501,764 | Pharmaceutical formulation and process comprising a solid dispersion of macrolide (tacrolimus) In force · USPTO record | In force | USPTO record | |
| US 7,918,830 | Safety Device for Drug Delivery Devices and Containers In force · High confidence | In force | High confidence | |
| US 8,382,717 | Safety Device for Drug Delivery Devices and Containers In force · High confidence | In force | High confidence | |
| US 8,858,506 | Safety Device for Drug Delivery Devices and Containers In force · High confidence | In force | High confidence | |
| US 8,563,032 | Formulation and manufacturing process for calcium acetate capsules In force · USPTO record | In force | USPTO record | |
| US 8,597,271 | Intravenous Bag/Line Safety Device In force · Medium confidence | In force | Medium confidence | |
| US 8,808,249 | Intravenous Bag/Line Safety Device In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 74: 2 patents in force now held by others · 2 lapsed for an unpaid fee · 30 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
7 pending · 1 abandoned · 6 no status recorded